Last Updated on December 22, 2024 by The Health Master
USFDA Approval
Indian pharmaceutical giant Lupin Limited has secured a significant win in the lucrative US market. The company recently announced receiving US Food and Drug Administration approval (USFDA approval) for its generic version of Travoprost Ophthalmic Solution USP, 0.004%.
This eye drop medication is used to treat glaucoma and ocular hypertension, conditions that cause a rise in pressure within the eye.
Generic Travoprost: Expanding Treatment Options
Lupin’s generic Travoprost ophthalmic solution, manufactured at their Pithampur facility in India, offers a more affordable alternative to the brand-name Travatan Z® Ophthalmic Solution, 0.004% by Sandoz Inc.
This USFDA approval broadens treatment options for patients with glaucoma and ocular hypertension, potentially increasing access to this vital medication.
Travoprost: Addressing a Multi-Million Dollar Market
According to IQVIA MAT March 2024 data, the brand-name Travatan Z® generated an estimated USD 77 million in annual sales within the US alone.
This highlights the substantial market size for Travoprost, and Lupin’s generic version is poised to capture a significant share.
Lupin: A Global Leader in Pharmaceuticals
Headquartered in Mumbai, India, Lupin is a leading player in the global pharmaceutical industry.
Their focus on innovation has resulted in a diverse portfolio encompassing branded and generic medications, alongside biotechnology products and active pharmaceutical ingredients (APIs).
Lupin’s reach extends across over 100 markets, including the US, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.
Key Takeaways:
- Lupin receives USFDA approval for its generic Travoprost ophthalmic solution.
- This medication is used to treat glaucoma and ocular hypertension.
- The generic version offers a more affordable treatment option.
- The market for Travoprost is estimated at USD 77 million annually in the US alone.
- Lupin’s approval strengthens their position as a global pharmaceutical leader.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for Colchicine capsules
USFDA Approval granted for Acetaminophen and Ibuprofen Tablets
USFDA approval granted for Loteprednol Etabonate Eye Drops
USFDA approval granted for this Eye Infection treatment
USFDA Approval granted for this Breast Cancer Drug: Alembic
India’s Fight to Reduce Reliance on China for Bulk Drug
Limit of Paracetamol (Acetamenophen) in Fixed Dose Combinations
USFDA approval granted for Colchicine capsules
India and Australia address issue of Pharma Pricing Control
Drug recall: Cipla, Glenmark recall these drugs
NPPA Reform Committee Includes Industry Representatives
USFDA Inspection: At Aurobindo Pharma Arm with 7 USFDA Observations
Pharmac South 2024 Gears Up for Special Conference on Revised Schedule M
New Ceiling Prices Announced for Coronary Stents in India
CDSCO-WHO Launches Virtual Webinar Series for Indian Regulators
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
